Paradigm Capital Management Inc. NY Makes New Investment in AtriCure, Inc. $ATRC

Key Points

• Paradigm Capital Management acquired 123,100 AtriCure shares worth approximately $3.44 million, giving it a 0.24% stake. Institutional investors collectively own 99.11% of the company.
• AtriCure insiders sold 44,246 shares valued at about $1.69 million over the past 90 days, while corporate insiders retain a 4.00% ownership stake.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $48.62. The company recently reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding expectations.

Paradigm Capital Management Inc. NY acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 123,100 shares of the medical device company's stock, valued at approximately $3,444,000. Paradigm Capital Management Inc. NY owned 0.24% of AtriCure at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Geneos Wealth Management Inc. acquired a new stake in AtriCure during the 2nd quarter worth about $37,000. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure in the second quarter valued at about $40,000. Allworth Financial LP acquired a new position in shares of AtriCure in the second quarter valued at about $43,000. Smartleaf Asset Management LLC raised its stake in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock worth $46,000 after purchasing an additional 429 shares during the last quarter. Finally, Fifth Third Bancorp purchased a new position in shares of AtriCure in the first quarter worth about $51,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 3,564 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the sale, the director directly owned 22,809 shares of the company's stock, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Maggie Yuen sold 3,500 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the transaction, the director owned 14,015 shares in the company, valued at $538,456.30. This trade represents a 19.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 44,246 shares of company stock valued at $1,691,895 in the last 90 days. Corporate insiders own 4.00% of the company's stock.

Wall Street Analysts Forecast Growth

ATRC has been the topic of a number of recent research reports. Weiss Ratings upgraded AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 19th. UBS Group decreased their price objective on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, July 28th. Wall Street Zen downgraded shares of AtriCure from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 2nd. Citigroup reiterated a "market outperform" rating on shares of AtriCure in a research note on Tuesday, July 21st. Finally, BTIG Research raised their target price on shares of AtriCure from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $48.62.

AtriCure Trading Up 0.6%

AtriCure stock opened at $49.28 on Tuesday. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $49.88. The stock's 50 day simple moving average is $36.25 and its two-hundred day simple moving average is $31.89. The firm has a market cap of $2.51 billion, a PE ratio of 234.68 and a beta of 1.20.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million for the quarter, compared to analysts' expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter last year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts anticipate that AtriCure, Inc. will post 0.2 earnings per share for the current year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source